Article
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Gastroenterology - 1 Feb 2015
Dore Gregory J, Lawitz Eric, Hézode Christophe, Shafran Stephen D, Ramji Alnoor, Tatum Harvey A, Taliani Gloria, Tran Albert, Brunetto Maurizia R, Zaltron Serena, Strasser Simone I, Weis Nina, Ghesquiere Wayne, Lee Samuel S, Larrey Dominique, Pol Stanislas, Harley Hugh, George Jacob, Fung Scott K, de Lédinghen Victor, Hagens Peggy, McPhee Fiona, Hernandez Dennis, Cohen David, Cooney Elizabeth, Noviello Stephanie, Hughes Eric A
Abstract excerpt
BACKGROUND & AIMS: Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.